Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
30 août 2021 08h19 HE
|
Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
Biomerica Reports Fiscal 2021 Year End Results
27 août 2021 20h37 HE
|
Biomerica, Inc.
Revenues increase 7.6% for fiscal 2021 vs fiscal 2020.InFoods® IBS Endpoint Trial expected to be fully enrolled in less than 2 weeks.Biomerica receives multiple notices of allowance for patents...
Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression
11 août 2021 08h19 HE
|
Biomerica, Inc.
Hundreds of millions of people worldwide suffer from depression IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has...
Biomerica Launches New Website For Its EZ Detect™ Colorectal Disease Screening Test
05 août 2021 08h19 HE
|
Biomerica, Inc.
Digital Health Advertising and Social Media Campaigns launching alongside new siteCurrently in discussion with major retailers to increase distribution of EZ Detect™ Colon Disease Test IRVINE,...
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
24 juin 2021 08h19 HE
|
Biomerica, Inc.
Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced...
Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
15 juin 2021 08h19 HE
|
Biomerica, Inc.
IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients)Broadens InFoods® global patent coverage with recently...
Biomerica to Participate in Upcoming Investor Conferences
04 juin 2021 08h00 HE
|
Biomerica, Inc.
IRVINE, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced that it will be participating in two upcoming...
Biomerica’s Fast 15-Minute Easy to Use COVID-19 Antigen Test Now Available With Simple Nasal Swab
11 mai 2021 08h19 HE
|
Biomerica, Inc.
Less invasive nasal swab taken from front opening of the nose is more comfortable for patientsTest can be performed by doctors, school and company nurses, and medical assistants, in any location...
Biomerica Reports 208% Increase In Q3 Fiscal 2021 Sales, Over Q3 Fiscal 2020
15 avr. 2021 10h31 HE
|
Biomerica, Inc.
Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods® diagnostic guided therapy technology, including...
Biomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update
15 janv. 2021 09h27 HE
|
Biomerica, Inc.
Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021 FDA actively reviewing Company’s EUA submission for its...